374 related articles for article (PubMed ID: 10684306)
21. Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects.
Zong J; Peng Q; Wang Q; Zhang T; Fan D; Xu X
Oncol Rep; 2009 Oct; 22(4):953-61. PubMed ID: 19724878
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen.
Hsu KF; Hung CF; Cheng WF; He L; Slater LA; Ling M; Wu TC
Gene Ther; 2001 Mar; 8(5):376-83. PubMed ID: 11313814
[TBL] [Abstract][Full Text] [Related]
23. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
24. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
25. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
27. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.
Chen YF; Lin CW; Tsao YP; Chen SL
J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
[TBL] [Abstract][Full Text] [Related]
31. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
32. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
33. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice.
Zhu X; Tommasino M; Vousden K; Sadovnikava E; Rappuoli R; Crawford L; Kast M; Melief CJ; Beverley PC; Stauss HJ
Scand J Immunol; 1995 Nov; 42(5):557-63. PubMed ID: 7481562
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
Ohlschläger P; Quetting M; Alvarez G; Dürst M; Gissmann L; Kaufmann AM
Int J Cancer; 2009 Jul; 125(1):189-98. PubMed ID: 19358269
[TBL] [Abstract][Full Text] [Related]
35. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
[TBL] [Abstract][Full Text] [Related]
37. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
[TBL] [Abstract][Full Text] [Related]
38. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
39. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
[TBL] [Abstract][Full Text] [Related]
40. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
